DSIP side effects by evidence tier: what the 1980s intravenous human studies recorded, what animal toxicology found, the uncontrolled reports on subcutaneous use, and the forty-year data gap.
DSIP — delta sleep-inducing peptide, the nonapeptide Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu — has a human tolerability record, which is more than most research peptides can say. The record is also forty years old, intravenous, and drawn from studies of a few dozen patients at a time, and nothing has been added to it since. This page reports what those studies described, what the animal work adds, and what the modern research market is doing without any data at all. It is a research reference beside the DSIP profile, not advice.
DSIP's human studies belong to the early 1980s, most of them from Dieter Schneider-Helmert and the Basel group that isolated the peptide, with Abba Kastin's laboratory supplying much of the pharmacology and the 1984 review in Neuroscience and Biobehavioral Reviews that summarised the first decade. They were small — typically single-figure to low-double-figure cohorts — used intravenous infusion, and predate modern adverse-event reporting standards. A 2006 review in the Journal of Neurochemistry called the whole literature "a still unresolved riddle": no receptor, no precursor gene, and inconsistent effects on sleep.
For tolerability that tier can show whether an acute, obvious reaction followed intravenous dosing. It cannot show incidence, because there is no denominator worth the name; it cannot show rare events; and it says nothing about the subcutaneous route, repeated dosing over weeks, or anything measured after 1995. The DSIP research overview covers the efficacy side of that record.
Schneider-Helmert's insomnia studies, summarised in Neuropsychobiology in 1983, gave DSIP intravenously at 25 nanomoles per kilogram — about 21 µg/kg — as single infusions or on several consecutive evenings to chronic insomniacs. The investigators reported improved sleep described as normalising rather than sedating, with no hangover effect the next day and no dependence. A 1984 study in Peptides gave a short intravenous course to patients with chronic, pronounced pain and reported reduced pain and improved mood without adverse effects. A 1984 open study in Neuropsychobiology gave DSIP to patients in opiate and alcohol withdrawal and reported reduced withdrawal symptoms, again without serious adverse events.
Across the sleep, pain and withdrawal trials the consistent statements are: no serious adverse events, no sedation or hangover, no dependence. Healthy volunteers given single doses often showed no effect of any kind, which the Basel group read as evidence that DSIP modulates rather than induces sleep. The DSIP dosage notes set out each study's route and amounts.
Early animal toxicology found a wide margin between doses that changed sleep EEG and doses that caused harm; effects in rabbits, rats and cats were frequently non-linear, with higher doses no more active than lower ones, and dependent on time of day. Rodent studies also reported that DSIP raised the seizure threshold and lowered body temperature, and reduced corticotropin and cortisol responses to stress — pharmacology that was never pursued clinically but that frames the theoretical concerns below. None of these animal doses, given intravenously, intraperitoneally or into the ventricles, translates to a human safety margin by body weight.
DSIP is degraded in plasma within minutes to roughly a quarter of an hour, with a protein-bound fraction that persists longer — the half-life calculator models the plasma figure. Every human study used intravenous infusion. The subcutaneous route common in the research community has never been characterised pharmacokinetically in any species, so how much peptide reaches circulation, over what interval, and with what local reaction is unknown. It is the single largest gap between the literature and how the compound is actually used. The sleep and longevity peptides article places DSIP beside the compounds it is usually stacked with, none of which has been studied in combination with it.
Research-community reports describe transient headache, next-day drowsiness or, paradoxically, disturbed or fragmented sleep, and occasional injection-site reactions. These are uncontrolled, unblinded self-reports with no denominator, from a route the literature never used, with no verification of what the vial contained. They cannot establish incidence or causation. The paradoxical-sleep reports are at least consistent with the animal finding that DSIP's effect depended on the time of day it was given.
Two follow from the pharmacology. A compound reported to modulate pituitary output — corticotropin and cortisol in the stress studies, luteinising hormone and growth hormone in others — could affect the stress and reproductive axes with repeated use. And a compound with a proposed opioid interaction, studied on that basis in withdrawal, could have additive effects with sedatives and opioids. Neither has been demonstrated; neither has been ruled out; no drug-interaction study of any kind exists.
DSIP's N-terminal tryptophan is light- and oxidation-sensitive, and the peptide is acidic and prone to proteolysis once in solution. A vial kept out of its carton, reconstituted for weeks or shipped warm will carry degradation products that HPLC would show. A share of injection-site and systemic reactions in unregulated use plausibly traces to those, to synthesis impurities or to endotoxin rather than to the nonapeptide. Reading the certificate of analysis is the only way to separate compound effects from product effects — see lab testing and COAs and the cold-chain and shelf-life guide. The DSIP 15 mg vial sold here is third-party HPLC tested by lot.
DSIP has no Health Canada market authorisation and no Drug Identification Number, and research-grade material is sold in Canada for laboratory use only. In September 2023 the U.S. FDA placed DSIP in category 2 of its section 503A bulk-substance evaluation, citing the absence of adequate safety data, which bars it from compounded medicines there. DSIP is not named on the WADA Prohibited List, though tested athletes should verify with their federation given the list's open categories.
Does DSIP have a documented side-effect profile? A thin one. Small intravenous studies in the early 1980s reported no serious adverse events, no sedation or hangover and no dependence. There is no modern trial, no long-term follow-up and no data on the subcutaneous route.
Is DSIP a sedative? Not as the literature describes it. The positive studies reported a shift toward slow-wave sleep without next-day hangover, and single doses in healthy volunteers often did nothing. Uncontrolled reports of next-day drowsiness exist but have no comparator.
Why does the subcutaneous route matter for safety? Because every human study infused DSIP intravenously. Subcutaneous absorption, exposure and local reactions have never been measured in any species.
What did the FDA decide about DSIP? In September 2023 it placed DSIP in category 2 for section 503A compounding, meaning it may not be used in compounded medicines in the United States, on the grounds that adequate safety data does not exist.
Is this medical advice? No. This page summarises published research for laboratory reference. It is not medical advice, not a safety assurance, and not a dosing recommendation. DSIP is sold here for research use only.
